
Twenty Years of G-CSF
Clinical and Nonclinical Discoveries
Springer (Publisher)
Published on 7. January 2012
Book
Hardback
XXII, 478 pages
978-3-0348-0217-8 (ISBN)
Description
Granulocyte colony-stimulating factor (G-CSF or GCSF) is a secreted glycoprotein that stimulates the proliferation and differentiation of granulocyte precursor cells, and induces mobilization of peripheral blood progenitor cells from the bone marrow. Development of recombinant human G-CSF has had a profound impact on the treatment of many diseases, including severe chronic neutropenia and cancer, and has enabled peripheral stem cell transplantation to supplant bone marrow transplantation in the autologous setting. This Milestones in Drug Therapy volume describes the experience of the last 20 years of treatment with recombinant human G-CSF, including the basic science, the use of recombinant human G-CSF in both the oncology and nononcology settings, and the safety and economics of its use. Many of the authors were the original investigators of recombinant human G-CSF and other authors are key researchers who provide their outlook for the next 20 years for use of and research with recombinant human G-CSF.
More details
Series
Edition
2012
Language
English
Place of publication
Basel
Switzerland
Publishing group
Springer Basel
Target group
Professional and scholarly
Research
Illustrations
41 s/w Abbildungen, 8 farbige Abbildungen, 50 s/w Tabellen
XXII, 478 p.
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 32 mm
Weight
910 gr
ISBN-13
978-3-0348-0217-8 (9783034802178)
DOI
10.1007/978-3-0348-0218-5
Schweitzer Classification
Other editions
Additional editions

Graham Molineux | MaryAnn Foote | Tara Arvedson
Twenty Years of G-CSF
Clinical and Nonclinical Discoveries
Book
02/2014
Springer
€213.99
Shipment within 10-15 days

Graham Molineux | MaryAnn Foote | Tara Arvedson
Twenty Years of G-CSF
Clinical and Nonclinical Discoveries
E-Book
01/2012
1st Edition
Springer
€213.99
Available for download
Content
Basic Science.- Use of rHuG-CSF in the Oncology Setting.- Use of rHuG-CSF in Non-Oncology Setting.- Safety and Economics.- The Next 20 Years.